Abnormal Neuropeptide Processing in the Brain Correlates with L-DOPA Side Effects in Parkinson's Disease | Research

The takeaway

Mass spectrometry imaging of primate brains revealed that L-DOPA-induced dyskinesia severity correlates with abnormally processed forms of dynorphin and substance P, suggesting disrupted neuropeptide signaling drives this debilitating side effect.

Truncated peptides correlate with dyskinesia severity
Dyskinesia severity tracked not with active neuropeptides but with their abnormally processed fragments — des-tyrosine dynorphins and shortened substance P — suggesting disrupted peptide processing is the key pathological event.

What the researchers found

Dyskinesia severity correlated with levels of abnormally processed peptides — des-tyrosine dynorphins, substance P (1-7), and substance P (1-9) — across multiple brain regions. Active neuropeptides (dynorphin B, dynorphin A (1-8), α-neoendorphin, substance P (1-11), neurokinin A) in the globus pallidus and substantia nigra correlated with putaminal L-DOPA concentrations. Truncated neuropeptides with reduced or altered receptor affinity correlated specifically with dyskinesia severity, particularly those in the direct pathway (dynorphins and tachykinins). The findings suggest increased neuropeptide tone in LID leads to abnormal processing as a compensatory mechanism.

Why it matters

Dyskinesia affects up to 80% of Parkinson's patients after 5-10 years of L-DOPA therapy and severely impacts quality of life. Current treatments are limited because the molecular mechanisms are poorly understood. This study reveals that the problem isn't simply too much or too little of certain neuropeptides — it's that they're being chopped into wrong-sized fragments with different biological activities. This shifts the therapeutic target from neuropeptide levels to neuropeptide processing enzymes.

How the study worked

Mass spectrometry imaging was used to visualize and quantify neuropeptides in brain tissue from MPTP-exposed parkinsonian Macaca mulatta (rhesus monkeys) with and without L-DOPA-induced dyskinesia. Regional mapping of both active neuropeptides and their truncated/abnormally processed forms was performed across basal ganglia structures. Correlations with dyskinesia severity and L-DOPA concentrations were calculated.

What this study cannot tell us

Non-human primate model (macaque) — while the best animal model for Parkinson's dyskinesia, species differences exist. MPTP-induced parkinsonism differs from idiopathic human PD in progression pattern. The study is correlative — it cannot prove that abnormal neuropeptide processing causes dyskinesia rather than being a consequence. Sample sizes were not specified in the abstract. The mass spectrometry imaging approach, while powerful for spatial mapping, has detection limits that may miss some peptide species.

How to read the evidence

Published in NPJ Parkinson's Disease, this is a high-quality preclinical study using state-of-the-art mass spectrometry imaging in the gold-standard primate model of Parkinson's dyskinesia. The spatial neuropeptide mapping and correlation analyses are methodologically rigorous. However, the findings are correlative and limited to a non-human primate model.

When this study was published

Published in 2022, this study uses cutting-edge mass spectrometry imaging technology to provide the most detailed neuropeptide mapping of L-DOPA dyskinesia published to date.

The bigger picture

This study represents a breakthrough in understanding the neuropeptide dimension of Parkinson's therapy complications. While most dyskinesia research has focused on dopamine receptors and downstream signaling, this work reveals that the opioid (dynorphin/enkephalin) and tachykinin (substance P/neurokinin A) neuropeptide systems are fundamentally disrupted. This could lead to entirely new treatment approaches — targeting neuropeptide-processing enzymes or specific neuropeptide receptors to manage dyskinesia without reducing L-DOPA's therapeutic benefit.

Questions still open

Which specific enzymes are responsible for the abnormal neuropeptide processing, and could they be pharmacologically targeted?
Would blocking the truncated neuropeptide fragments (rather than the full-length peptides) reduce dyskinesia without affecting L-DOPA's benefit?
Do human Parkinson's patients show the same patterns of abnormal neuropeptide processing seen in this primate model?

Common questions

Why does L-DOPA cause involuntary movements in Parkinson's patients?

This study reveals a new piece of the puzzle: long-term L-DOPA use disrupts how the brain processes neuropeptides like dynorphin and substance P. Instead of producing the correct active forms, the brain makes abnormal truncated fragments that don't bind to receptors properly. These misfiring neuropeptide signals in movement-controlling brain regions appear to drive the involuntary movements (dyskinesia) that affect most Parkinson's patients over time.

Could this lead to better treatments for Parkinson's dyskinesia?

Yes — by identifying specific abnormally processed neuropeptide fragments that correlate with dyskinesia severity, this study points to new drug targets. Instead of reducing L-DOPA (which helps movement), therapies could potentially target the enzymes that create these harmful fragments or block the fragments from disrupting brain circuits. This is a fundamentally different approach from current dyskinesia treatments.

Read the original research

Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia.

NPJ Parkinson's disease, 8(1), 41

View on PubMed ↗Publisher’s paper ↗

Citation

Hulme, Heather; Fridjonsdottir, Elva; Vallianatou, Theodosia; Shariatgorji, Reza; Nilsson, Anna; Li, Qin; Bezard, Erwan; Andrén, Per E. (2022). Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia.. NPJ Parkinson's disease, 8(1), 41. https://doi.org/10.1038/s41531-022-00299-7